Undisclosed information: How Indoleamine 2,3-Dioxygenase 2 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1)
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
The 1989 Nobel prize winner in Chemistry, Prof. Thomas R. Cech from the BioFrontiers Institute, USA has published a research paper in the 13 December 2012 Nature (492(7428):285-9; and I.F: >42) stating that “The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity.” This study provides mechanistic insights into how TPP1 regulates telomerase function.
In connection with this finding, Dr Boominathan, Founder Director-cum-chief scientist of GBMD, reports that: MiRNA-based therapy for Human Cancer: Indoleamine 2,3-Dioxygenase 2 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) via down regulation of its target gene.
Given that cancer causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) a cheaper alternative to the existing expensive drugs; (ii) a side-effect-free natural product-based drug; (iii) a way to effectively treat cancers that are resistant to anti-cancer drugs; and (iv) a way to effectively treat and eradicate metastatic progression of cancer.
Indoleamine 2,3-Dioxygenase 2, by increasing the expression of its target gene, it may decrease the expression of Tripeptidyl Peptidase 1 (TPP1). Remarkably, over 90% human tumors over express telomerase, suggesting that inhibition of its activity may increase the efficacy of anticancer therapy. Considered together, this study suggests that pharmacological formulations encompassing “Indoleamine 2,3-Dioxygenase 2 activators“ may be used to treat human cancers.
* Research cooperation
Citation: Boominathan, L., Molecular therapy for Human Cancer: Indoleamine 2,3-Dioxygenase 2 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) via down regulation of its target gene, 7/October/2015, 10.29 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com